Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À§¾Ï¼¼Æ÷ÁÖ¿¡¼­ p53 À¯ÀüÀÚ ÇüÁúµµÀÔÀÌ À§¾Ï¼¼Æ÷ÁÖÀÇ Malignant Phenotype¿¡ ¹ÌÄ¡´Â ¿µÇâ Effect on Malignant Phenotypes of Gastric Cancer Cell Line after p53 Gene Transduction

´ëÇѾÏÇÐȸÁö 1998³â 30±Ç 3È£ p.508 ~ 520
¼Ò¼Ó »ó¼¼Á¤º¸
¶ó¼±¿µ/Sun Young Rha

Abstract

¼­·Ð
ÀÎü ¾ÏÁ¶Á÷¿¡¼­ °üÂûµÇ´Â °¡Àå ÈçÇÑ À¯ÀüÀÚ º¯È­´Â p53 À¯ÀüÀÚ µ¹¿¬º¯ÀÌ·Î Áö±Ý±îÁö Æó
¾Ï, À¯¹æ¾Ï, À§¾Ï µî¿¡¼­ ÀÌ À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ¿¡ ÀÇÇÑ ´Ü¹éÀÇ ºñÈ°¼ºÈ­°¡ º¸°íµÇ¾ú´Ù. ´ëÀå
¾Ï°ú À¯¹æ¾Ï¿¡¼­´Â p53 À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ°¡ ¾Ï¹ß»ýÀÇ Ãʱâ´Ü°è¿¡ °ü¿©ÇÏ´Â ¹Ý¸é, ³úÁ¾¾ç¿¡
¼­´Â ºñ±³Àû ¾Ç¼ºµµ°¡ ³·Àº ¼º»ó¼¼Æ÷Á¾¿¡¼­ ¾Ç¼ºµµ°¡ ³ôÀº ´ÙÇü¼º ½Å°æ±³¾ÆÁ¾À¸·Î ÀÌÇà½Ã¿¡
p53 À¯ÀüÀÚÀÇ ºñÈ°¼ºÈ­°¡ °ü¿©ÇÒ °¡´É¼ºÀÌ Á¦½ÃµÇ¾ú´Ù. ¹Ý¸é À§¾Ï¿¡¼­´Â p53ÀÌ ¾ÏÈ­ °úÁ¤Áß
ÁøÇà, Áï ÀüÀÌ¿¡ °ü°èÇÒ °¡´É¼ºÀÌ Á¦½ÃµÇ¾ú´Ù.
¾ÏÀÇ ÀüÀÌ´Â ¾Ï¼¼Æ÷ÀÇ Áõ½Ä, ħÀ±, Ç÷·ù¸¦ ÅëÇÑ ¿ø°ÝÀå±â·ÎÀÇ À̵¿, È£¹ßÀå±â·ÎÀÇ ºÎÂø ¹×
½Å»ýÇ÷°ü»ý¼º µîÀÇ ´Ù´Ü°è °úÁ¤À» °ÅÄ£ ÈÄ ¿Ï·áÇÏ°Ô µÈ´Ù. ÀÌ¿Í °°Àº ´Ù´Ü°è ÀüÀÌ °úÁ¤À»
¿Ï·áÇϱâ À§Çؼ­´Â ¾Ï¼¼Æ÷°¡ ¿©·¯°¡Áö »ý¹°ÇÐÀû Ư¼º(biological phenotypes)À» ¹ßÇöÇØ¾ß ÇÑ
´Ù. Áï Á¾¾ç¼ºÀåÀÎÀÚ ¹ßÇö¿¡ ÀÇÇÑ Á¾¾çÇü¼º´É, ±âÁúºÐÇØÈ¿¼ÒÀÇ »ý¼º´É, ¼¼Æ÷ À̵¿´É, ÁÖÀ§ ±â
ÁúÁ¶Á÷À¸·ÎÀÇ ºÎÂø´É ¹× Ç÷°ü»ý¼º À¯µµ´ÉÀÌ ¹ßÇöÇØ¾ß ¿ø°ÝÀüÀÌ°¡ ¹ß»ýÇÑ´Ù. µû¶ó¼­ p53 À¯
ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ¿¡ ÀÇÇØ ¿ø°ÝÀüÀÌ°¡ Áõ°¡ÇÑ´Ù¸é, p53À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ°¡ ¹ß»ýÇÑ ¼¼Æ÷¿Í ¹ß
»ýÇÏÁö ¾ÊÀº ¼¼Æ÷ »çÀÌ¿¡´Â »ó¼úÇÑ ¿©·¯°¡Áö »ý¹°ÇÐÀû È°¼ºÀÇ Â÷ÀÌ°¡ ÀÖÀ» °ÍÀ¸·Î »ý°¢µÈ
´Ù.
p53 ´Ü¹éÁúÀº 393°³ÀÇ ¾Æ¹Ì³ë»êÀ¸·Î ±¸¼ºµÇ¾î ÀÖÀ¸¸ç, ¾Ï À¯¹ßÀ¯ÀüÀÚ¿¡ ÀÇÇÑ ¼¼Æ÷º¯ÇüÀ»
¾ïÁ¦½ÃÅ°°Å³ª DNA°¡ ¼Õ»óµÈ ¼¼Æ÷ÀÇ ºÐ¿­Áֱ⸦ G1±â¿¡ Á¤Áö½ÃÄÑ DNA¼Õ»óÀ» ȸº¹½ÃÅ°°Å
³ª ¼¼Æ÷»ç¸ê(apoptosis)¸¦ À¯µµÇÑ´Ù. µû¶ó¼­ Á¡ µ¹¿¬º¯ÀÌ, À¯ÀüÀÚ ¼Ò½Ç ȤÀº Àç¹èÄ¡ µîÀÌ Á¤
»ó p53À¯ÀüÀÚ¿¡ ¹ß»ýÇÒ °æ¿ì º¯ÇüµÈ ´Ü¹éÁúÀÌ »ý¼ºµÇ¾î Á¾¾ç¼¼Æ÷ÀÇ Áõ½ÄÀ» ¾ïÁ¦ÇÏÁö ¸øÇÒ
»Ó ¾Æ´Ï¶ó Á¤»óÇü p53 ´Ü¹éÁú°ú º¹ÇÕü¸¦ Çü¼ºÇÏ¿© Á¤»óÇü p53 ´Ü¹éÀÇ ±â´ÉÀ» ¾ïÁ¦½ÃŲ´Ù.
Á¾¾ç¾ïÁ¦ À¯ÀüÀڷμ­ p53 À¯ÀüÀÚÀÇ ±â´ÉÀº °ñÀ°Á¾ ¼¼Æ÷ÁÖ¿¡ Á¤»ó p53 À¯ÀüÀÚ¸¦ ÇüÁúµµÀÔ½Ã
¿¡ ¾Ï¼¼Æ÷ÀÇ Áý¶ôÇü¼º ¹× ¼ºÀå¼Óµµ°¡ °¨¼ÒµÊÀ¸·Î ÀϺΠÁõ¸íµÇ¾ú´Ù. ¾ÏÀÇ ÀüÀÌ °úÁ¤¿¡¼­ p53
À¯ÀüÀÚÀÇ ¿ªÇÒÀº ÀÓ»óÀûÀ¸·Î´Â ºñ¼Ò¼¼Æ÷¼º Æó¾Ï ȯÀÚÀÇ ¾Ï Á¶Á÷¿¡¼­ p53À¯ÀüÀÚ µ¹¿¬º¯ÀÌ
¹ß»ý½Ã¿¡ ÁÖÀ§ ÀÓÆÄÀý·Î ÀüÀÌÀ²ÀÌ ³ôÀ½ÀÌ °üÂûµÇ¾ú´Ù. ½ÇÇèÀûÀ¸·Î´Â ÁãÀÇ ¹æ±¤¾Ï¼¼Æ÷¿¡ µ¹
¿¬º¯ÀÌ 953 À¯ÀüÀÚ¸¦ ÇüÁúµµÀԽà ÀüÀÌ°¡ Áõ°¡ÇÔÀÌ È®ÀεǾúÀ¸¸ç, ¸î °¡Áö ÀÎü Á¾¾ç¿¡¼­ Á¤
»ó p53 À¯ÀüÀÚ ÇüÁúµµÀԽà Á¾¾ç¼¼Æ÷ÀÇ ¾Ç¼ºÇüÁúÀÇ ¹ßÇöÀ» ¾ïÁ¦ÇÏ¿© Á¾¾ç¼¼Æ÷ÀÇ ¼ºÀåÀ» ¾ï
Á¦ÇÔÀÌ ¹àÇôÁ³´Ù.
ÀúÀÚ µîÀº À§¾Ï¼¼Æ÷ÁÖ¿¡¼­ retrovirus¸¦ ÀÌ¿ëÇÏ¿© Á¤»ó p53 À¯ÀüÀÚ¸¦ ÇüÁúµµÀԽà À§¾Ï¼¼Æ÷
ÁÖÀÇ ¼ºÀå¾ïÁ¦ È¿°ú°¡ p53 À¯ÀüÀÚÀÇ µ¹¿¬º¯À̸¦ ÇÔÀ¯ÇÏ°í ÀÖ´Â À§¾Ï¼¼Æ÷ÁÖ¿¡¼­ È®ÀÎÇÒ ¼ö
ÀÖ¾ú´Ù. ¹Ý¸é, Á¤»óÇüÀÇ p53 À¯ÀüÀÚ¸¦ ÇÔÀ¯ÇÏ´Â À§¾Ï¼¼Æ÷ÁÖ¿¡¼­´Â ¼ºÀå¾ïÁ¦ È¿°ú¸¦ °üÂûÇÏÁö
¸øÇÏ¿´´Ù. µû¶ó¼­ º» ¿¬±¸¿¡¼­´Â À§¾Ï ¼¼Æ÷ÁÖ¿¡¼­ Á¤»ó p53 À¯ÀüÀÚÀÇ ÀüÀ̾ïÁ¦ ±â´ÉÀ» Á¶»ç
Çϱâ À§ÇØ p53 À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ°¡ ¹ß»ýÇÑ À§¾Ï¼¼Æ÷ÁÖ¿Í Á¤»ó p53 À¯ÀüÀÚ°¡ Á¸ÀçÇÏ´Â ¼¼
Æ÷ÁÖ¿¡¼­ »ý¹°ÇÐÀû Ư¼ºÀÇ Â÷ÀÌ ¿©ºÎ¸¦ Á¶»çÇÏ¿´´Ù. ´ÙÀ½, µ¹¿¬º¯ÀÌ p53 À¯ÀüÀÚ¸¦ ÇÔÀ¯ÇÏ´Â
¼¼Æ÷ÁÖ¿¡ Á¤»ó p53 À¯ÀüÀÚ¸¦ ÇüÁúµµÀÔ ÇÑ ÈÄ ¼¼Æ÷Áõ½Ä¿¡´Â ¿µÇâÀ» ¹ÞÁö ¾Ê´Â cloneÀ» ¼±Á¤
ÇÏ¿© ¿©·¯ °¡Áö »ý¹°ÇÐÀû Ư¼ºÀÇ º¯È­¸¦ ºñ±³ÇÔÀ¸·Î¼­ p53 À¯ÀüÀÚ ¿ä¹ýÀÇ Ç× ÀüÁö Ä¡·á·Î
¼­ÀÇ °¡´É¼ºÀ» Á¶»çÇÏ¿´´Ù.

Purpose : To evaluate the effect of wild type p53 gene transduction on the malignant
phenotypes for metastasis in gastric cancer, we compared the biological phenpotypes of
gastric cancer cell lines based on p53 gene status. Then, after retrovirus-mediated
wild-type p53 gene transduction, we compared those phenotypes among parent YCC-3
cell line, vector transduced YCC-3v cell line and a clone of YCC-3C3.
Material and methods : Four human gastric cancer cell lines were used; YCC-1
(mutant), YCC-2(wild), YCC-3(mutant) and AGS(wild). DNAs of the cell lines were
analyzed to evaluate the mobility shift with PCR-SSCP. Tumorigenecity and proliferation
were evaluated by soft agar assay and proliferation assay. Migratory capacity was
measured by adhesion assay and Boyden chamber assay. p53 protein expression was
measured by Western blot analysis and VEGF, WAF-1 were measured by ELISA
assay. Angiogenic activity was measured by cross-feeding assay and cell cycle analysis
was performed by flow cytometry. In vivo tumorigenicity was measured by xenograft in
nude mice.
Results : YCC-3 cell line with mutant p53 gene expressed all the phenotypes for the
metastasis such as tumorigenicity, migration and angiogenesis. In a stable clone of
YCC-3C3, no differences were found in proliferation, cell cycle and WAF-1
expression when compared to those of the control YCC-3v and parent YCC-3 cell line,
even if increased p53 protein production was found by Western blot analysis. However,
both in vitro and in vivo tumorigenicity were decreased in a stably transduced
YCC-3C3 clone. The adhesive capacity was also decreased in
YCC-3C3 clone whereas the endothelial cell growth stimulatory effect and
VEGF production showed no difference compared to those of the YCC-3v cell line.
Conclusion : Wild-type p53 gene transduction in gastric cancer cell line decreased
tumorigenicity which resulted from decreased colony forming activity and adhesive
capacity but not formed changes of angiogenic activity. This suggested the possible
application of anti-metastasis strategy with p53 gene therapy in gastric cancer.

Å°¿öµå

Wild-type p53; Malignant phenotypes; Transduction; Gastric cancer;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS